Cargando…
Multinational corporations and infectious disease: Embracing human rights management techniques
BACKGROUND: Global health institutions have called for governments, international organisations and health practitioners to employ a human rights-based approach to infectious diseases. The motivation for a human rights approach is clear: poverty and inequality create conditions for infectious diseas...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323175/ https://www.ncbi.nlm.nih.gov/pubmed/25671119 http://dx.doi.org/10.1186/2049-9957-3-39 |
_version_ | 1782356502629056512 |
---|---|
author | Salcito, Kendyl Singer, Burton H Weiss, Mitchell G Winkler, Mirko S Krieger, Gary R Wielga, Mark Utzinger, Jürg |
author_facet | Salcito, Kendyl Singer, Burton H Weiss, Mitchell G Winkler, Mirko S Krieger, Gary R Wielga, Mark Utzinger, Jürg |
author_sort | Salcito, Kendyl |
collection | PubMed |
description | BACKGROUND: Global health institutions have called for governments, international organisations and health practitioners to employ a human rights-based approach to infectious diseases. The motivation for a human rights approach is clear: poverty and inequality create conditions for infectious diseases to thrive, and the diseases, in turn, interact with social-ecological systems to promulgate poverty, inequity and indignity. Governments and intergovernmental organisations should be concerned with the control and elimination of these diseases, as widespread infections delay economic growth and contribute to higher healthcare costs and slower processes for realising universal human rights. These social determinants and economic outcomes associated with infectious diseases should interest multinational companies, partly because they have bearing on corporate productivity and, increasingly, because new global norms impose on companies a responsibility to respect human rights, including the right to health. METHODS: We reviewed historical and recent developments at the interface of infectious diseases, human rights and multinational corporations. Our investigation was supplemented with field-level insights at corporate capital projects that were developed in areas of high endemicity of infectious diseases, which embraced rights-based disease control strategies. RESULTS: Experience and literature provide a longstanding business case and an emerging social responsibility case for corporations to apply a human rights approach to health programmes at global operations. Indeed, in an increasingly globalised and interconnected world, multinational corporations have an interest, and an important role to play, in advancing rights-based control strategies for infectious diseases. CONCLUSIONS: There are new opportunities for governments and international health agencies to enlist corporate business actors in disease control and elimination strategies. Guidance offered by the United Nations in 2011 that is widely embraced by companies, governments and civil society provides a roadmap for engaging business enterprises in rights-based disease management strategies to mitigate disease transmission rates and improve human welfare outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2049-9957-3-39) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4323175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43231752015-02-11 Multinational corporations and infectious disease: Embracing human rights management techniques Salcito, Kendyl Singer, Burton H Weiss, Mitchell G Winkler, Mirko S Krieger, Gary R Wielga, Mark Utzinger, Jürg Infect Dis Poverty Research Article BACKGROUND: Global health institutions have called for governments, international organisations and health practitioners to employ a human rights-based approach to infectious diseases. The motivation for a human rights approach is clear: poverty and inequality create conditions for infectious diseases to thrive, and the diseases, in turn, interact with social-ecological systems to promulgate poverty, inequity and indignity. Governments and intergovernmental organisations should be concerned with the control and elimination of these diseases, as widespread infections delay economic growth and contribute to higher healthcare costs and slower processes for realising universal human rights. These social determinants and economic outcomes associated with infectious diseases should interest multinational companies, partly because they have bearing on corporate productivity and, increasingly, because new global norms impose on companies a responsibility to respect human rights, including the right to health. METHODS: We reviewed historical and recent developments at the interface of infectious diseases, human rights and multinational corporations. Our investigation was supplemented with field-level insights at corporate capital projects that were developed in areas of high endemicity of infectious diseases, which embraced rights-based disease control strategies. RESULTS: Experience and literature provide a longstanding business case and an emerging social responsibility case for corporations to apply a human rights approach to health programmes at global operations. Indeed, in an increasingly globalised and interconnected world, multinational corporations have an interest, and an important role to play, in advancing rights-based control strategies for infectious diseases. CONCLUSIONS: There are new opportunities for governments and international health agencies to enlist corporate business actors in disease control and elimination strategies. Guidance offered by the United Nations in 2011 that is widely embraced by companies, governments and civil society provides a roadmap for engaging business enterprises in rights-based disease management strategies to mitigate disease transmission rates and improve human welfare outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2049-9957-3-39) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-03 /pmc/articles/PMC4323175/ /pubmed/25671119 http://dx.doi.org/10.1186/2049-9957-3-39 Text en © Salcito et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Salcito, Kendyl Singer, Burton H Weiss, Mitchell G Winkler, Mirko S Krieger, Gary R Wielga, Mark Utzinger, Jürg Multinational corporations and infectious disease: Embracing human rights management techniques |
title | Multinational corporations and infectious disease: Embracing human rights management techniques |
title_full | Multinational corporations and infectious disease: Embracing human rights management techniques |
title_fullStr | Multinational corporations and infectious disease: Embracing human rights management techniques |
title_full_unstemmed | Multinational corporations and infectious disease: Embracing human rights management techniques |
title_short | Multinational corporations and infectious disease: Embracing human rights management techniques |
title_sort | multinational corporations and infectious disease: embracing human rights management techniques |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323175/ https://www.ncbi.nlm.nih.gov/pubmed/25671119 http://dx.doi.org/10.1186/2049-9957-3-39 |
work_keys_str_mv | AT salcitokendyl multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques AT singerburtonh multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques AT weissmitchellg multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques AT winklermirkos multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques AT kriegergaryr multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques AT wielgamark multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques AT utzingerjurg multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques |